Girard Sharp LLP is investigating potential claims on behalf of Quanterix Corporation (NASDAQ: QTRX) shareholders.
If you are a current or former Qaunterix Corporation shareholder, please fill out our form or call (866) 981-4800 for a free consultation.
Qaunterix Stock Drops Over 19% Following Company Report
Qaunterix Corporation is a life sciences company specializing in the development and marketing of biochemical tests to improve precision health. On November 13, 2024, a report by the company disclosed “an error in the capitalization of labor and overhead costs for prior periods going back to at least 2021”. Due to this error, the company’s financial statements are considered unreliable. The price of Quanterix Corporation’s stock has dropped 19% following this news.
If you are a current or former Qaunterix Corporation shareholder, please call (866) 981-4800 for a free consultation.
Our Commitment to Excellence
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. We recently obtained a $36.5 million securities settlement against Maxar Technologies, a space imagery company, after its share price collapsed following its acquisition of DigitalGlobe. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
